# Docetaxel

## TAXOTERE inj 80mg/4mL

| TAH Drug Code      | [ITAX8](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITAX8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | [Breast cancer] Operable (adjuvant treatment): TAC regimen: 75 mg/m2 every 3 weeks for 6 courses in combination with doxorubicin 50mg/m2 and cyclophosphamide 500 mg/m2; Locally advanced or metastatic: 100 mg/m2 every 3 weeks as a single agent; 75 mg/m2 every 3 weeks in combination with doxorubicin 50 mg/m2 as first-line therapy; In combination with weekly trastuzumab: 100 mg/m2 every 3 weeks; In combination with capecitabine: 75 mg/m2 every 3 weeks.  [Non-small cell lung cancer] Chemotherapy-naive patients: 75 mg/m2 every 3 weeks in combination with cisplatin 75 mg/m2 or carboplatin with a target AUC of 6 mg/mL‧min; Patients with prior failure of platinum?based chemotherapy: 75 mg/m2 every 3 weeks as a single agent.  [Prostate cancer] 75 mg/m2 every 3 weeks in combination with oral prednisone or prednisolone 5 mg twice daily. [Gastric adenocarcinoma] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil. [Head and neck cancer] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil for 3 or 4 cycles, followed by radiation therapy. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count <1,500/mm3. Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Body fluid retention (6.5-67%), Vasodilatation (27%), Alopecia (56-98%), Disorder of skin and/or subcutaneous tissue, Nail changes (8-41%), Pruritus, Rash, Diarrhea (23-78%), Inflammatory disease of mucous membrane, Nausea (38-81%), Stomatitis (19-69%), Vomiting (22-67%), Anemia, All Grades (67-97%), Leukopenia, All Grades (84-99%), Neutropenia, All Grades (41-100%), Asthenia (53-81%), Neuropathy (4-30%), Amenorrhea (62%), Fever of unknown origin (31-47%). Serious: Generalized exanthematous pustulosis, acute, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Enterocolitis, Anemia, Grade 3 or 4 (4-18%), Febrile neutropenia (3-26%), Leukopenia, Grade 3 or 4 (32-49%), Neutropenia, Grade 3 or 4 (32-94%), Thrombocytopenia (3-44%), Liver function tests outside reference range, Anaphylaxis (Rare), Metastatic malignant neoplasm, Renal failure, Pulmonary embolism, Infectious disease (22-39%), Tumor lysis syndrome.                                                                                                                                                   |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/docetaxel-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

## Taxotere inj 20mg/1mL

| TAH Drug Code      | [ITAXO](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=ITAXO)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck cancer.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Dosing             | [Breast cancer] Operable (adjuvant treatment): TAC regimen: 75 mg/m2 every 3 weeks for 6 courses in combination with doxorubicin 50mg/m2 and cyclophosphamide 500 mg/m2; Locally advanced or metastatic: 100 mg/m2 every 3 weeks as a single agent; 75 mg/m2 every 3 weeks in combination with doxorubicin 50 mg/m2 as first-line therapy; In combination with weekly trastuzumab: 100 mg/m2 every 3 weeks; In combination with capecitabine: 75 mg/m2 every 3 weeks.  [Non-small cell lung cancer] Chemotherapy-naive patients: 75 mg/m2 every 3 weeks in combination with cisplatin 75 mg/m2 or carboplatin with a target AUC of 6 mg/mL‧min; Patients with prior failure of platinum?based chemotherapy: 75 mg/m2 every 3 weeks as a single agent.  [Prostate cancer] 75 mg/m2 every 3 weeks in combination with oral prednisone or prednisolone 5 mg twice daily. [Gastric adenocarcinoma] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil. [Head and neck cancer] 75 mg/m2 every 3 weeks in combination with cisplatin and fluorouracil for 3 or 4 cycles, followed by radiation therapy. |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Severe hypersensitivity to docetaxel or any component of the formulation; severe hypersensitivity to other medications containing polysorbate 80; neutrophil count <1,500/mm3. Canadian labeling: Additional contraindications (not in the US labeling): Severe hepatic impairment; pregnancy; breastfeeding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Adverse Effects    | Common: Body fluid retention (6.5-67%), Vasodilatation (27%), Alopecia (56-98%), Disorder of skin and/or subcutaneous tissue, Nail changes (8-41%), Pruritus, Rash, Diarrhea (23-78%), Inflammatory disease of mucous membrane, Nausea (38-81%), Stomatitis (19-69%), Vomiting (22-67%), Anemia, All Grades (67-97%), Leukopenia, All Grades (84-99%), Neutropenia, All Grades (41-100%), Asthenia (53-81%), Neuropathy (4-30%), Amenorrhea (62%), Fever of unknown origin (31-47%). Serious: Generalized exanthematous pustulosis, acute, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Enterocolitis, Anemia, Grade 3 or 4 (4-18%), Febrile neutropenia (3-26%), Leukopenia, Grade 3 or 4 (32-49%), Neutropenia, Grade 3 or 4 (32-94%), Thrombocytopenia (3-44%), Liver function tests outside reference range, Anaphylaxis (Rare), Metastatic malignant neoplasm, Renal failure, Pulmonary embolism, Infectious disease (22-39%), Tumor lysis syndrome.                                                                                                                                                   |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| More Info          | [UpToDate](https://www.uptodate.com/contents/docetaxel-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

